HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to ...

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New ...

Artificial intelligence (AI)-based ECG interpretation outperformed standard pathways for the detection of occlusive ...

HeartBeam, Inc. BEAT shares are trading higher Tuesday after the company announced a strategic partnership with Mount Sinai ...

Results from the RAPID-MIRACLE trial have found, for the first time, that the widely used MIRACLE2 risk score can be applied outside a hospital setting to accurately predict brain injury following a ...

An artificial intelligence (AI)-based method for interpreting ECGs performed better than standard approaches in detecting occlusive myocardial infarction (MI), according to a study presented at ESC ...

Complete financial results are included in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026, which has been filed with the U.S. Securities and Exchange ...

(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a strategic collaboration with the Icahn School of Medicine at ...

HeartBeam (Nasdaq:BEAT) announced today that it entered into a strategic collaboration with the Icahn School of Medicine at Mount Sinai.

Researchers at King's College London have shown that a widely used cardiac arrest risk score can be applied before patients ...

The rapid digitization of healthcare is transforming patient care, but it is also creating new vulnerabilities as cyber threats grow more sophisticated and widespread. From ransomware attacks to data ...

Romano-Ward syndrome, the most common congenital long QT disorder, often causes exertion- or stimulus-triggered syncope and ...